Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo, Affymetrix, Agilent, Ingenuity, GE Healthcare


GeneGo has launched the newest version of its MetaCore integrated data mining suite, featuring more than 300 functional maps of human biology, additional parsers for importing data directly from Affymetrix and Agilent microarrays, analyzed data from Silicon Genetics’ GeneSpring and Rosetta’s Resolver, SAGE, proteomics, and metabolomics data.

Ingenuity has released the latest version of its flagship product, Ingenuity Pathways Analysis. The software enables researchers to analyze multiple datasets across different experimentation platforms while identifying key functions and pathways that distinguish biological states. The product is used for dose-response assessment, patient stratification for clinical trials, time course experiments, and simultaneous analysis of gene lists and protein lists.

GE Healthcare, based in Chalfont St. Giles, UK, announced this week that it has launched its Rat Whole Genome Bioarray for use on the firm’s CodeLink microarray platform. The array has roughly 34,000 gene targets, and according to the firm, detects transcripts at levels lower than any other commercially available platform.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.